Search results
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with...
WPRI Providence· 5 days ago("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations ...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by PNC Financial Services Group Inc.
ETF DAILY NEWS· 4 days agoPNC Financial Services Group Inc. reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.0% during the 4th quarter, according to the company ...
Biogen's new acquisition target reveals 'provocative' trial results - Boston Business Journal
The Business Journals· 7 hours agoJust days after Biogen Inc. announced it was buying Human Immunology Biosciences (HI-Bio) for $1.15...
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers -...
NBC 17 Raleigh· 6 days agoPomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and ...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 5 days agoThis decision was based on top-line data from the phase I/II ALSpire study, wherein treatment with...
Needham & Company LLC Reiterates “Buy” Rating for Biogen (NASDAQ:BIIB)
ETF DAILY NEWS· 5 days agoBiogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Wednesday, Benzinga reports.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to...
FOX 23 News Albany· 5 days agoThe Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
...Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class...
Benzinga· 3 days agoThe law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. BIIB securities between February 3, 2022 and February ...
IGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive
Investing.com· 6 days agoIGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive
Biogen to buy San Francisco startup developing a drug for kidney disease for $1.2B - Boston Business...
The Business Journals· 6 days agoIn addition to the upfront fee, Biogen (Nasdaq: BIIB) could also pay up to $650 million in potential...